Malignant Glioma

Positive interim safety results reported from Reolysin phase I study

Published in Cancer Weekly, January 21st, 2003

Oncolytics Biotech, Inc., (ONCY) announced positive interim safety results from the phase I component of its clinical study examining the use of Reolysin in the treatment of recurrent malignant glioma, the most aggressive form of brain cancer.

The company reported that Reolysin appeared to be well tolerated when surgically delivered into the brain during the treatment of the first six patients.

Determination of the safety of Reolysin is the primary purpose of the phase I study. The study is examining the use of a single, intratumoral injection of Reolysin delivered using imaging-guided surgery, in patients with malignant glioma that has recurred...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-01-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry